Resources

The_case_for_biotech_88a63ebc32.png
Biotechnology has hit the headlines during the COVID-19 pandemic as companies race for vaccines and treatments, but its growth prospects extend beyond this period. Australian investors may be well familiar with this industry, given the dominance of CSL, but may be missing exposure to the international market, in particular, the US, the global centre of biotechnology. Download the full article here What is biotechnology? Biotechnology is a sub-industry of the healthcare sector and specifically refers to technologies that use biological processes, capturing companies that focus on research, development, manufacturing and/or marketing of products based on biological and genetic information. The different types of biotechnology include biological drugs, vaccines, immunotherapy, gene therapy, orphan drugs and genetic engineering. ...
monitor-default-image.png
This week's highlights Equity markets mostly declined last week, with second-wave fears and cautious Fed comments halting the rally. Bearish funds (BBUS, BBOZ and BEAR) were amongst the top performers, while technology-related companies in China (CNEW) and the US (FANG) outperformed. Global energy companies (FUEL), banks (BNKS) and US small-and mid-cap companies (IJR and IJH) were amongst the poorest performers. Precious metals all rallied strongly last week. GOLD returned 5.1% for the week, while the diversified ETFS Physical Precious Metals Basket (ETPMPM) returned 3.8%. Gold miner (GDX) was also amongst the top performers. Oil declined, with OOO returning -7.8%. Total flows into domestically domiciled ETFs were $285m, while outflows totalled just $14m. Domestic cash fund AAA saw the biggest inflows for the week, followed by IOZ. Consumer staples fund IXI saw the largest outflows. Bearish fund BBOZ was the most traded fund for the week, followed by domestic equity fund VAS. GOLD and OOO saw above average volumes. ...